Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Jakafi (ruxolitinib) – Treatment of Myelofibrosis

Ruxolitinib restrains the growth of malignant cells and also controls cytokines that contribute to a hypermetabolic state.

Go Top